Minimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

In this study, the performance of the commercially available LymphoTrack high-throughput sequencing assay was assessed for determining residual disease burden in patients with various T-cell malignancies.

Source: Journal of Molecular Diagnostics - March 2, 2023 Category: Pathology Authors: Jack K. Tung, Diwash Jangam, Chandler C. Ho, Eula Fung, Michael S. Khodadoust, Youn H. Kim, James L. Zehnder, Henning Stehr, Bing M. Zhang Tags: Regular articles Source Type: research